Sign In
Buy NMRD
$0.0002
+0 (+0%)
At Close: Jun 03, 2026
Nemaura Medical Announces SFDA Approval of sugarBEAT®
08:30am, Thursday, 17'th Aug 2023
Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializi
Nemaura Medical Secures $6.5m in Non-Dilutive Funding
04:05pm, Friday, 11'th Aug 2023
Loughborough, England, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and su
Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023
09:25am, Friday, 14'th Jul 2023
Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializi
Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton
08:00am, Tuesday, 21'st Mar 2023
LOUGHBOROUGH, March 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non
Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement
08:00am, Wednesday, 15'th Mar 2023
LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non
Nemaura Medical Announces Receipt of Notice from Nasdaq
04:57pm, Thursday, 09'th Mar 2023
LOUGHBOROUGH, March 09, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-in
Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference
08:15am, Thursday, 16'th Feb 2023
Loughborough, England, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable sensors and
Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference
08:00am, Wednesday, 11'th Jan 2023
Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de
Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022
08:15am, Thursday, 01'st Dec 2022
Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de
Nemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors Conference
08:00am, Friday, 11'th Nov 2022
Loughborough, England, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de
Nemaura Medical to Present at the 24th Annual H.C. Wainwright Global Investment Conference
08:30am, Tuesday, 06'th Sep 2022
Loughborough, England, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable gluc
Nemaura Medical, Inc. (NMRD) Reports Q1 Loss, Lags Revenue Estimates
11:17am, Monday, 15'th Aug 2022
Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of -6.25% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Nemaura Medical to Present at the Planet MicroCap Showcase 2022
08:30am, Monday, 25'th Apr 2022
Loughborough, England, April 25, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and s
Nemaura Medical to Present at the Maxim Group 2022 Virtual Growth Conference
04:24pm, Thursday, 24'th Mar 2022
Loughborough, England, March 24, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and s
Nemaura Medical''s sugarBEAT(R) CGM Device Met With Early Success
06:08pm, Monday, 14'th Mar 2022 Benzinga
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Nemaura Medical (NASDAQ: NMRD ), a medical technology company, has sought to develop and offer economical, compact and convenient non-invasive devices that could alleviate the pain associated with frequent skin pricking among diabetic patients. The devices also simultaneously promote routine glucose testing in a bid to control blood glucose levels more effectively. Nemaura offers two flagship constant glucose monitoring (“CGM”) products: the sugarBEAT(R), a non-invasive wearable diagnostic device, and MiBoKo, an application that supports personalized lifestyle coaching programs. A recent article reads: “The company’s revolutionary sugarBEAT(R) CGM device seeks to provide users with non-invasive glucose monitoring; as described by the company, it works by drawing a small amount of selected molecules, such as glucose, into a patch placed on the skin… The device has already met with early success, with Nemaura Medical revealing projections for orders of 2 million sensors and 15,000 CGM devices from the United Kingdom alone over the next two years, with the aim of targeting the over 4.9 million diabetics in the U.K. currently as well as the 13.6 million people at increased risk of contracting type 2 diabetes.” To view the full article, visit https://ibn.fm/RSuzy About Nemaura Medical Inc.
